Serum bone Gla protein (BGP) during treatment of hyperthyroidism and hypothyroidism. A longitudinal study.
Serum bone gamma-carboxyglutamic acid-containing (Gla) protein (BGP) was measured before and with initially 2 weeks, later 4-8 weeks intervals for 20-58 weeks during treatment of patients with hyperthyroidism (n = 10) and hypothyroidism (n = 4). Biochemical euthyroidism was obtained in the hyperthyroid patients after a median of 3 weeks (range 1-8 weeks), and in the hypothyroid patients after a median of 17 weeks (range 10-27 weeks). Serum BGP levels closely followed the thyroid state, being high respectively low in the hyperthyroid and hypothyroid state and reaching a stable plateau just at the time biochemical euthyroidism was obtained. These data suggest that osteoblastic activity is enhanced in hyperthyroidism and reduced in hypothyroidism, and that normalization occurs in close conjunction with the normalization of the thyroid state, without any delay, indicating a direct effect on the function of the excisting osteoblasts by the thyroid hormones.
Faber
J
J
Department of Medicine E, Frederiksberg Hospital, Copenhagen, Denmark.
Perrild
H
H
Johansen
J S
JS
D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000188:drug therapy*; D007037:Hypothyroidism / Q000097:blood / Q000188:drug therapy*; D008137:Longitudinal Studies; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D015675:Osteocalcin / Q000097:blood*; D011863:Radioimmunoassay; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood / Q000627:therapeutic use*; D014284:Triiodothyronine / Q000097:blood
D014284:Triiodothyronine; D015675:Osteocalcin; D008713:Methimazole; D013972:Thyrotropin; D013974:Thyroxine